Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roderick L Beijersbergen

Showing results (1-10 of 98) with videos related to

Pageof 10
Sort By:
Nature Cancer|February 5, 2022
Old drugs with new tricksRoderick L Beijersbergen
Cancer Discovery|May 16, 2012
Functional subtyping of breast cancerRoderick L Beijersbergen, René Bernards
Ebiomedicine|June 29, 2021
It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivitiesCor Lieftink, Roderick L Beijersbergen
Future Oncology (London, England)|December 15, 2010
Exploration of synthetic lethal interactions as cancer drug targetsHendrik J Kuiken, Roderick L Beijersbergen
Idrugs : the Investigational Drugs Journal|November 4, 2010
Using large-scale RNAi screens to identify novel drug targets for cancerJeroen H Nijwening, Roderick L Beijersbergen
Methods in Molecular Biology (Clifton, N.J.)|September 2, 2016
Pooled shRNA Screening in Mammalian Cells as a Functional Genomic Discovery PlatformKatarzyna Jastrzebski, Bastiaan Evers, Roderick L Beijersbergen
Molecular Systems Biology|July 3, 2014
The Good, the Bad, and the Ugly: in search of gold standards for assessing functional genetic screen qualityBastiaan Evers, Rene Bernards, Roderick L Beijersbergen
Nature Methods|August 25, 2006
shRNA libraries and their use in cancer geneticsRené Bernards, Thijn R Brummelkamp, Roderick L Beijersbergen
Cell Cycle (Georgetown, Tex.)|January 18, 2011
Screening for modulators of cisplatin sensitivity: unbiased screens reveal common themesJeroen H Nijwening, Hendrik J Kuiken, Roderick L Beijersbergen
Plos One|October 8, 2011
The histone demethylase Jarid1b (Kdm5b) is a novel component of the Rb pathway and associates with E2f-target genes in MEFs during senescenceJeroen H Nijwening, Ernst-Jan Geutjes, Rene Bernards, et al.
Pageof 10

Showing results (1-10 of 98) with videos related to

Sort By:
Pageof 10
Nature Cancer|February 5, 2022
Old drugs with new tricksRoderick L Beijersbergen
Cancer Discovery|May 16, 2012
Functional subtyping of breast cancerRoderick L Beijersbergen, René Bernards
Ebiomedicine|June 29, 2021
It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivitiesCor Lieftink, Roderick L Beijersbergen
Future Oncology (London, England)|December 15, 2010
Exploration of synthetic lethal interactions as cancer drug targetsHendrik J Kuiken, Roderick L Beijersbergen
Idrugs : the Investigational Drugs Journal|November 4, 2010
Using large-scale RNAi screens to identify novel drug targets for cancerJeroen H Nijwening, Roderick L Beijersbergen
Methods in Molecular Biology (Clifton, N.J.)|September 2, 2016
Pooled shRNA Screening in Mammalian Cells as a Functional Genomic Discovery PlatformKatarzyna Jastrzebski, Bastiaan Evers, Roderick L Beijersbergen
Molecular Systems Biology|July 3, 2014
The Good, the Bad, and the Ugly: in search of gold standards for assessing functional genetic screen qualityBastiaan Evers, Rene Bernards, Roderick L Beijersbergen
Nature Methods|August 25, 2006
shRNA libraries and their use in cancer geneticsRené Bernards, Thijn R Brummelkamp, Roderick L Beijersbergen
Cell Cycle (Georgetown, Tex.)|January 18, 2011
Screening for modulators of cisplatin sensitivity: unbiased screens reveal common themesJeroen H Nijwening, Hendrik J Kuiken, Roderick L Beijersbergen
Plos One|October 8, 2011
The histone demethylase Jarid1b (Kdm5b) is a novel component of the Rb pathway and associates with E2f-target genes in MEFs during senescenceJeroen H Nijwening, Ernst-Jan Geutjes, Rene Bernards, et al.
Pageof 10